TCM
APLS

Tenor Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Tenor Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-17,548
Closed -$423K – 168
2019
Q3 		$423K Buy
+17,548
New +$483K 0.03% 112

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Tenor Capital Management's APLS Position: Q4 2019 in Review

Tenor Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q4 2019, closing a stake of 17,548 shares — an estimated $423K sold.

Tenor Capital Management first reported a position in APLS in Q3 2019 and held it in 1 quarter. The position peaked at $423K in Q3 2019. 133 funds tracked by Wall St. Rank hold APLS as of Q4 2019.

  • Tenor Capital Management reported no remaining Apellis Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Tenor Capital Management sold 17,548 Apellis Pharmaceuticals shares in Q4 2019, an estimated $423K.
  • Tenor Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Tenor Capital Management's Apellis Pharmaceuticals position peaked at $423K in Q3 2019.
  • 133 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2019.

Based on Tenor Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.